<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102982</url>
  </required_header>
  <id_info>
    <org_study_id>Shandong PH</org_study_id>
    <nct_id>NCT04102982</nct_id>
  </id_info>
  <brief_title>Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer</brief_title>
  <acronym>MWA in NSCLC</acronym>
  <official_title>Shandong Provincial Hospital Affiliated to Shandong University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on&#xD;
      day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the&#xD;
      primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21&#xD;
      days.&#xD;
&#xD;
      The primary end point is overall survival. The second end points include progression free&#xD;
      survival, objective response rate and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1：Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days.&#xD;
Arm 2：Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>The proportion of Patients achieved complete response or partial response up to 16 weeks</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of first documented date of death from any cause，assessed up to 24 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>The proportion and grade of patients had adverse events up to 24 months</time_frame>
    <description>The adverse events of both microwave and camrelizumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>Microwave ablation plus camrelizumab group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camrelizumab group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the group are treated with camrelizumab alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Patients will be treated with camrelizumab alone.</description>
    <arm_group_label>Camrelizumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Camrelizumab plus microwave ablation</intervention_name>
    <description>In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.</description>
    <arm_group_label>Microwave ablation plus camrelizumab group</arm_group_label>
    <other_name>Camrelizumab plus MWA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 75 years old&#xD;
&#xD;
          2. Cytologically or pathologically verified non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          3. Patients with distant metastases or postoperative recurrence&#xD;
&#xD;
          4. EGFR or ALK sensitive mutations are negative (all patients, including&#xD;
             non-adenocarcinoma patients)&#xD;
&#xD;
          5. At least one line of platinum-based doublet chemotherapy was administrated&#xD;
&#xD;
          6. Eastern Cancer Cooperative Group（ECOG）Performance Status（PS）of 0 to 1&#xD;
&#xD;
          7. At least two measurable tumors (in other words a measurable tumor lesion exclusive&#xD;
             primary tumors)&#xD;
&#xD;
          8. Asymptomatic brain metastases or symptomatic brain metastases under control&#xD;
&#xD;
          9. If treated with irradiation，at least one month interval between radiation and&#xD;
             randomization 10）Cardiopulmonary function, laboratory test indicators without ablation&#xD;
             or chemotherapy contraindications&#xD;
&#xD;
        11) Informed conssent can be obtained 12) Sufficient tissue specimens for PD-L1 or TMB or&#xD;
        blood samples were provided (1 week before treatment, 1 week after ablation, and once every&#xD;
        two months for immune evaluation) for subsequent analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mixed lung cancer contains neuroendocrine tumor, small cell lung cancer or sarcoma&#xD;
&#xD;
          2. Suffering from other malignant tumors within five years&#xD;
&#xD;
          3. EGFR, ALK sensitive mutations are positive or unknown&#xD;
&#xD;
          4. ECOG PS≥2&#xD;
&#xD;
          5. Uncontrolled pleural effusion or pericardial effusion&#xD;
&#xD;
          6. Uncontrolled symptomatic brain metastases&#xD;
&#xD;
          7. Previously anti-PD-1, anti-PD-L1, anti-CTLA-4 or Car-T immunotherapy&#xD;
&#xD;
          8. severe interstitial pneumonia with severe diffuse dysfunction&#xD;
&#xD;
          9. Autoimmune diseases require long-term hormone therapy patients&#xD;
&#xD;
         10. Patients required consistent application of prednisone&#xD;
&#xD;
         11. Uncontrolled pulmonary infection or antibiotics stopped within 1 month&#xD;
&#xD;
         12. Acute cardiovascular and cerebrovascular diseases such as acute cerebral infarction&#xD;
             and acute coronary syndrome within 1 month&#xD;
&#xD;
         13. Patients during pregnancy or lactation&#xD;
&#xD;
         14. Life expectance of 3 months or less&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Ye</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Ye</last_name>
    <phone>+8653168773171</phone>
    <email>yexitaian2014@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhigang Wei</last_name>
    <phone>+8653168773171</phone>
    <email>weizhigang321321@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Binzhou Medical University Hospital</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <zip>+86 256600</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao shui Chen, M.D</last_name>
      <phone>+86 15169959936</phone>
      <email>byfychenss@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dezhou People's Hospital</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <zip>+86 253000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu ting Dong</last_name>
      <phone>+86 13969286066</phone>
      <email>dyt1963@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Dezhou</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <zip>+86 253000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun tang Wang, M.D</last_name>
      <phone>+86 13181378288</phone>
      <email>dzeyxwct@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Military General Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+83 250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing wang Bi, M.D</last_name>
      <phone>+86 15963119538</phone>
      <email>jingwangbi@outlook.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Shandong Academy of Medical Sciences</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+86 250001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya hong Sun, M.D</last_name>
      <phone>13606415915</phone>
      <email>sunyahong0915@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital affliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+86053168773172</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Ye, M.D.</last_name>
      <phone>+86 0531 68773172</phone>
      <email>yexintaian2014@163.com</email>
    </contact>
    <contact_backup>
      <last_name>gang Z Wei, M.D.</last_name>
      <phone>+86 0531 68773171</phone>
      <email>weizhigang321321@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>+86 272000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun ye Wang, M.D</last_name>
      <phone>+86 13563771996</phone>
      <email>jiningwangjunye@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng Cancer Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>+86 252000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing liang Feng, M.D</last_name>
      <phone>+86 15339949567</phone>
      <email>fql-123@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Taishan Medical University</name>
      <address>
        <city>Taian</city>
        <state>Shandong</state>
        <zip>+86 271000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben hua Zhang, M.D</last_name>
      <phone>+86 15169887577</phone>
      <email>zhangbenhua1964@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Liberation Army 88 Hospital</name>
      <address>
        <city>Taian</city>
        <state>Shandong</state>
        <zip>+86 271000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li cheng Zhang, M.D</last_name>
      <phone>+86 13605383651</phone>
      <email>zhanglc88@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>+86 262000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo hua Yu, M.D</last_name>
      <phone>+86 13685368817</phone>
      <email>ghyry@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>+86 264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang ming Zhang, M.D</last_name>
      <phone>+86 18660079893</phone>
      <email>zhanglmdr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tengzhou center of people's hospital</name>
      <address>
        <city>Zaozhuang</city>
        <state>Shandong</state>
        <zip>+86 277000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai xian Zhang, M.D</last_name>
      <phone>+86 18663069829</phone>
      <email>kaixianzhang@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 22, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Xin Ye</investigator_full_name>
    <investigator_title>Head of Section</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>Microwave ablation</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Progression free survival</keyword>
  <keyword>Objective response rate</keyword>
  <keyword>Safety</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Principle of confidentiality</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

